KCC 07 is an MBD2 (Methyl-CpG-binding domain protein 2) inhibitor that prevents binding of MBD2 to methylated DNA and activates brain specific angiogenesis inhibitor 1 (BAI1)/p53 signaling.
Physicochemical Properties
| Molecular Formula | C14H11N3OS |
| Molecular Weight | 269.321641206741 |
| Exact Mass | 269.06 |
| Elemental Analysis | C, 62.44; H, 4.12; N, 15.60; O, 5.94; S, 11.90 |
| CAS # | 315702-75-1 |
| PubChem CID | 704347 |
| Appearance | White to yellow solid powder |
| LogP | 3.1 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 19 |
| Complexity | 292 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | GIGNWEDIMLUWCT-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C14H11N3OS/c18-11-5-3-4-10(8-11)16-14-17-13(9-19-14)12-6-1-2-7-15-12/h1-9,18H,(H,16,17) |
| Chemical Name | 3-[(4-pyridin-2-yl-1,3-thiazol-2-yl)amino]phenol |
| Synonyms | KCC 07; KCC07; KCC-07 |
| HS Tariff Code | 2934.99.03.00 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | MBD2 (methyl-CpG-binding domain protein 2) |
| ln Vitro | In vitro treatment of MB cells with KCC-07 (10 μM; 72 hours) greatly decreased their proliferation, in line with anti-proliferative BAI1/p53/p21 signaling [1]. treatment of MB cells) significantly reduced the binding of MBD2 to the ADGRB1 promoter and reinstated the production of BAI1 mRNA and protein in MB cells that had been BAI1-silenced [1]. |
| ln Vivo | KCC-07 (100 mg/kg; intraperitoneal injection; 5 days/week; athymic nude mice) treatment significantly extended the lifespan of MB xenografts in vivo and suppressed tumor growth [1]. |
| Cell Assay |
Cell viability assay [1] Cell Types: Medulloblastoma (MB) cells Tested Concentrations: 10 μM Incubation Duration: 72 hrs (hours) Experimental Results: Dramatically inhibited MB cell growth in vitro. Western Blot Analysis [1] Cell Types: Medulloblastoma (MB) Cell Tested Concentrations: 10 μM Incubation Duration: 48 hrs (hours) Experimental Results: In BAI1-silenced MB cells, MBD2 binding to the ADGRB1 promoter was largely eliminated. |
| Animal Protocol |
Animal/Disease Models: outbred athymic nude mice (female; 8-10 weeks old) injected with MB cells [1] Doses: 100 mg/kg Route of Administration: intraperitoneal (ip) injection; 5 days per week Experimental Results: Dramatically prolonged MB xenogeneic How long the graft survives in the body. |
| References |
[1]. BAI1 Suppresses Medulloblastoma Formation by Protecting p53 From Mdm2-Mediated Degradation. Cancer Cell. 2018 Jun 11;33(6):1004-1016.e5. |
Solubility Data
| Solubility (In Vitro) |
DMSO: 54~125 mg/mL (200.5~464.1 mM) Ethanol: 54 mg/mL |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (7.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7131 mL | 18.5653 mL | 37.1306 mL | |
| 5 mM | 0.7426 mL | 3.7131 mL | 7.4261 mL | |
| 10 mM | 0.3713 mL | 1.8565 mL | 3.7131 mL |